Adam Lawrence

Adam Lawrence specializes in in vitro diagnostic (IVD) devices focused on monitoring ketone (acetoacetate) levels and glucose concentrations. Their products include reagent-based ketone test strips, electrometric glucose test strips, and a home-use clinical chemistry system designed for simultaneous monitoring of multiple analytes. These devices are intended for point-of-care use and personal health tracking.

Adam Lawrence is based in the United States. As a U.S.-based manufacturer, its devices must comply with FDA regulations governing in vitro diagnostics. The company’s products are classified under FDA’s Class I and Class II categories, which determine the regulatory oversight level based on risk. For example, test strips like the ketone or glucose strips fall under Class II due to their role in managing patient health, while some systems may qualify for Class I if they pose minimal risk.

Yes, Adam Lawrence’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. The UDI system ensures traceability and transparency in the medical device supply chain, allowing healthcare providers, regulators, and patients to identify and verify specific devices. Listing in the UDI database is a requirement for FDA-regulated devices, including those manufactured by Adam Lawrence.

Adam Lawrence’s devices are classified under the FDA’s Class I and Class II categories. Class I devices generally pose the lowest risk and may require general controls (e.g., good manufacturing practices) for compliance. Class II devices, like reagent-based ketone or glucose test strips, involve moderate risk and may require additional performance standards or post-market surveillance. Classification depends on factors like the device’s intended use, potential harm if misused, and the level of regulatory oversight needed to ensure safety and effectiveness.